$IMRX Cashflow Statement | Understand Stock

$IMRX

$3.83 +$0.12 (3.23%) Close

$IMRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustment to reconcile to net loss to net cash used in operating activities:
Depreciation and amortization expense
Reduction in carrying amount of right-of-use assets
Amortization of intangibles
Stock-based compensation expense
Net amortization of premium (accretion of discount) on marketable securities
Net accretion of discount on marketable securities
Loss on disposal of fixed assets
Deferred tax benefit
Change in assets and liabilities:
(Increase) decrease in:
Accounts receivable
Prepaid expenses and other current assets
Other assets
Increase (decrease) in:
Accounts payable
Accrued expenses
Lease liabilities
Other liabilities

Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Cash acquired in business combination
Net cash (used in) provided by investing activities

Cash flows from financing activities:
Payment of offering costs
Public Offering
Total payment of offering costs
Proceeds from exercise of stock options
Proceeds from exercise of warrants
Proceeds from issuance of common stock
At the market offering
Warrant
Public Offering
Private Placement
Total proceeds from issuance of common stock
Payment of initial public offering costs
Proceeds from employee stock purchase plan
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of noncash investing and financing information:
Conversion of convertible Series A and B preferred stock into common stock
Business combination non cash
Class A common stock issued for business combination
Reduction of right-of-use asset and lease liability in connection with lease modification
Property and equipment in accounts payable/accrued expenses
Deferred offering costs in accounts payable/accrued expenses
Cashless exercise of prefunded warrants

Comments